CWM
BMY.RT

Cranbrook Wealth Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Cranbrook Wealth Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-92
Closed – – 431
2020
Q4 		$0 Hold
92
– – ﹤0.01% 341
2020
Q3 		$0 Sell
92
-239
-72% -$683 ﹤0.01% 289
2020
Q2 		$1K Buy
331
+239
+260% +$862 ﹤0.01% 261
2020
Q1 		$0 Hold
92
– – ﹤0.01% 288
2019
Q4 		$0 Buy
+92
New +$239 ﹤0.01% 301

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Cranbrook Wealth Management's BMY.RT Position: Q1 2021 in Review

Cranbrook Wealth Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 92 shares.

Cranbrook Wealth Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Cranbrook Wealth Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Cranbrook Wealth Management sold 92 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Cranbrook Wealth Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Cranbrook Wealth Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Cranbrook Wealth Management's 13F filing for Q1 2021, filed 6 May 2021.